144 related articles for article (PubMed ID: 37149546)
1. ASO Author Reflections: Adjuvant Chemotherapy for Resected Biliary Tract Cancers-Does One Size Fit All?
Rhodin KE; Lidsky ME
Ann Surg Oncol; 2023 Aug; 30(8):4822-4823. PubMed ID: 37149546
[No Abstract] [Full Text] [Related]
2. ASO Author Reflections: Adjuvant Chemoradiation for Patients with Resected Biliary Tract Cancers.
Dee EC; Freret ME; Wo JY
Ann Surg Oncol; 2020 Dec; 27(13):5173-5174. PubMed ID: 32748150
[No Abstract] [Full Text] [Related]
3. ASO Author Reflections: Phase II Trial of Adjuvant Chemotherapy with S-1 for Node-Positive Biliary Tract Cancer (N-SOG 09).
Ebata T; Mizuno T
Ann Surg Oncol; 2020 Jul; 27(7):2357-2358. PubMed ID: 32206952
[No Abstract] [Full Text] [Related]
4. Adjuvant Chemotherapy in Resected Biliary Tract Cancer.
Primrose JN
Ann Surg Oncol; 2020 Jul; 27(7):2127-2129. PubMed ID: 32378086
[No Abstract] [Full Text] [Related]
5. Adjuvant chemotherapy for resected biliary tract cancers: A fluorouracil-based scheme beats out a gemcitabine-based scheme for the win.
Hu YF; Ma WJ; Jin YW; Li FY
Hepatology; 2024 May; 79(5):965-969. PubMed ID: 37870296
[No Abstract] [Full Text] [Related]
6. Feasibility study of postoperative adjuvant chemotherapy with S-1 in patients with biliary tract cancer.
Nakachi K; Konishi M; Ikeda M; Shimada K; Okusaka T; Saiura A; Ishii H; Sugiyama M; Furuse J; Sakamoto H; Shimamura T; Ohta T
Int J Clin Oncol; 2018 Oct; 23(5):894-899. PubMed ID: 29705976
[TBL] [Abstract][Full Text] [Related]
7. A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in curatively resected patients with biliary tract cancer: adjusting the dose of adjuvant chemotherapy according to the surgical procedures.
Takahara T; Nitta H; Hasegawa Y; Itou N; Takahashi M; Nishizuka S; Wakabayashi G
Cancer Chemother Pharmacol; 2012 May; 69(5):1127-33. PubMed ID: 22207029
[TBL] [Abstract][Full Text] [Related]
8. Surgical treatment and adjuvant chemotherapy for patients with biliary tract cancer: single institution experience of 100 patients.
Harada N; Shirabe K; Yoshizumi T; Ikegami T; Uchiyama H; Soejima Y; Yamashita Y; Saeki H; Oki E; Kawanaka H; Morita M; Ikeda T; Matsuura H; Okadome K; Maehara Y
Fukuoka Igaku Zasshi; 2013 Dec; 104(12):539-48. PubMed ID: 24693682
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of S-1 Adjuvant Chemotherapy for Resected Biliary Tract Cancer: A Retrospective Propensity-Matched Analysis.
Yoshida M; Yanagimoto H; Tsugawa D; Akita M; Urade T; Nanno Y; Fukushima K; Gon H; Komatsu S; Asari S; Kido M; Toyama H; Ajiki T; Fukumoto T
Am Surg; 2024 Jun; 90(6):1279-1289. PubMed ID: 38226586
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant chemotherapy for resectable biliary tract cancer: current status and future direction.
Konishi M
J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):301-5. PubMed ID: 22262202
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials.
Nara S; Esaki M; Ban D; Takamoto T; Shimada K; Ioka T; Okusaka T; Ishii H; Furuse J
Jpn J Clin Oncol; 2020 Dec; 50(12):1353-1363. PubMed ID: 33037430
[TBL] [Abstract][Full Text] [Related]
12. BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care.
Rizzo A; Brandi G
Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):483-485. PubMed ID: 33307876
[TBL] [Abstract][Full Text] [Related]
13. Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer.
Rizzo A; Brandi G
Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):547-554. PubMed ID: 33571059
[No Abstract] [Full Text] [Related]
14. Postoperative adjuvant treatments for biliary tract cancer.
Furuse J
J Hepatobiliary Pancreat Surg; 2008; 15(5):463-7. PubMed ID: 18836797
[TBL] [Abstract][Full Text] [Related]
15. Current standards and future perspectives in adjuvant treatment for biliary tract cancers.
Lamarca A; Edeline J; McNamara MG; Hubner RA; Nagino M; Bridgewater J; Primrose J; Valle JW
Cancer Treat Rev; 2020 Mar; 84():101936. PubMed ID: 31986437
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the effects of adjuvant concurrent chemoradiotherapy and chemotherapy for resected biliary tract cancer.
Kim H; Heo MH; Kim JY
BMC Gastroenterol; 2020 Jan; 20(1):20. PubMed ID: 31992208
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: which is better in patients with radically resected extrahepatic biliary tract cancer?: a non-randomized, single center study.
Lim KH; Oh DY; Chie EK; Jang JY; Im SA; Kim TY; Kim SW; Ha SW; Bang YJ
BMC Cancer; 2009 Sep; 9():345. PubMed ID: 19781103
[TBL] [Abstract][Full Text] [Related]
18. Role of adjuvant and neoadjuvant therapy for resectable biliary tract cancer.
Nara S; Esaki M; Ban D; Takamoto T; Mizui T; Shimada K
Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):537-545. PubMed ID: 33793366
[No Abstract] [Full Text] [Related]
19. ASO Author Reflections: The Feasibility of Preoperative FDG-Positive Lymph Nodes of Resectable Biliary Tract Cancers for Postoperative Prognosis.
Kubo M; Kobayashi S
Ann Surg Oncol; 2022 Feb; 29(2):945-946. PubMed ID: 34586520
[No Abstract] [Full Text] [Related]
20. Feasibility of S-1 adjuvant chemotherapy after major hepatectomy for biliary tract cancers: An exploratory subset analysis of JCOG1202.
Kobayashi S; Nakachi K; Ikeda M; Konishi M; Ogawa G; Sugiura T; Yanagimoto H; Morinaga S; Wada H; Shimada K; Takahashi Y; Nakagohri T; Kamata K; Shimizu Y; Ajiki T; Hirano S; Gotohda N; Ueno M; Okusaka T; Furuse J
Eur J Surg Oncol; 2024 Feb; 50(2):107324. PubMed ID: 38157649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
